Secord, A. A., Sill, M., Lankes, H., Birrer, M., Monk, B., Liu, Y., … Nixon, A. (2025). PREDICTIVE BLOOD-BASED BIOMARKERS IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL-BASED CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: RESULTS FROM GOG-0240. In International Journal of Gynecological Cancer (Vol. 35, pp. 102158–102158). Elsevier BV. https://doi.org/10.1016/j.ijgc.2025.102158

Secord, Angeles Alvarez, Michael Sill, Heather Lankes, Michael Birrer, Bradley Monk, Yingmiao Liu, Mark Starr, et al. “PREDICTIVE BLOOD-BASED BIOMARKERS IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL-BASED CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: RESULTS FROM GOG-0240.” In International Journal of Gynecological Cancer, 35:102158–102158. Elsevier BV, 2025. https://doi.org/10.1016/j.ijgc.2025.102158.

Secord AA, Sill M, Lankes H, Birrer M, Monk B, Liu Y, et al. PREDICTIVE BLOOD-BASED BIOMARKERS IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL-BASED CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: RESULTS FROM GOG-0240. In: International Journal of Gynecological Cancer. Elsevier BV; 2025. p. 102158–102158.

Secord, Angeles Alvarez, et al. “PREDICTIVE BLOOD-BASED BIOMARKERS IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL-BASED CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: RESULTS FROM GOG-0240.” International Journal of Gynecological Cancer, vol. 35, no. 11, Elsevier BV, 2025, pp. 102158–102158. Crossref, doi:10.1016/j.ijgc.2025.102158.

Secord AA, Sill M, Lankes H, Birrer M, Monk B, Liu Y, Starr M, Brady C, Leitao M, Ramondetta L, Clair K, Newton M, Guntupalli S, Richardson D, Disilvestro P, Cantuaria G, Iii CL, Billingsley C, Mcdonald M, Lea J, Ueland F, Chambers L, Tewari KS, Nixon A. PREDICTIVE BLOOD-BASED BIOMARKERS IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL-BASED CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: RESULTS FROM GOG-0240. International Journal of Gynecological Cancer. Elsevier BV; 2025. p. 102158–102158.